Earnings Results
Cannara Biotech (NASDAQ:LOVE) reported quarterly earnings results on July 15, 2026 that exceeded analyst expectations.
The Consumer Cyclical company reported earnings per share of $0.05, beating the consensus estimate of $-0.18 by $0.23 per share. Revenue came in at $31.8M, missing the estimate of $52.4M.
Company Overview
Cannara Biotech's stock moved following the earnings release. The stock currently trades at $18.24 with a market capitalization of $185.4M.
Cannara Biotech's earnings outperformance reflects execution that exceeded Wall Street's expectations. Earnings beats can lead to upward estimate revisions from analysts, which often correlate with sustained stock price appreciation over the following weeks as models are updated.
The 128% beat relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Cannara Biotech should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.
Cannara Biotech Earnings History
| Quarter | EPS Actual | EPS Est. | Surprise |
| Q3 (Jul 2026) | $0.05 | $-0.18 | +127.8% |
| Q1 (Jun 2026) | $-0.76 | $-0.93 | +18.3% |
| Q2 (Apr 2026) | $0.02 | $-0.40 | +105.0% |
| Q4 (Mar 2026) | $2.19 | $2.11 | +3.8% |
Related Tools: Earnings Calendar | View LOVE Stock Page
Frequently Asked Questions
When does Cannara Biotech report earnings?
Check the latest earnings dates on our LOVE earnings page or the Earnings Calendar.
Did LOVE beat earnings estimates?
See the full Q3 results including EPS actual vs estimate on our LOVE earnings page.